Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis

Sreedhar R. Tummalapalli, Rohit Bhat, Agnieszka Chojnowski, Monika Prorok, Tamara Kreiss, Ronald Goldberg, Stacie Canan, Natalie Hawryluk, Deborah Mortensen, Vikram Khetani, Jerome Zeldis, John J. Siekierka, David P. Rotella

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Lymphatic filariasis infects over 120 million people worldwide and can lead to significant disfigurement and disease. Resistance is emerging with current treatments, and these therapies have dose limiting adverse events; consequently new targets are needed. One approach to achieve this goal is inhibition of parasitic protein kinases involved in circumventing host defense mechanisms. This report describes structure-activity relationships leading to the identification of a potent, orally bioavailable stress activated protein kinase inhibitor that may be used to investigate this hypothesis.

Original languageEnglish
Pages (from-to)210-214
Number of pages5
JournalACS Medicinal Chemistry Letters
Issue number3
StatePublished - 8 Mar 2018


  • Parasitic kinase inhibitor
  • lymphatic filariasis
  • stress-activated kinase


Dive into the research topics of 'Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis'. Together they form a unique fingerprint.

Cite this